Single-cell analysis of human lung epithelia reveals concomitant expression of the SARS-CoV-2 receptor ACE2 with multiple virus receptors and scavengers in alveolar type II cells

Guangchun Han^{1*}, Ansum Sinjab^{2*}, Warapen Treekitkarnmongkol², Patrick Brennan³, Kieko Hara², Kyle Chang⁴, Elena Bogatenkova³, Beatriz Sanchez-Espiridon², Carmen Behrens⁵, Boning Gao⁶, Luc Girard⁶, Jianjun Zhang⁵, Boris Sepesi⁷, Tina Cascone⁵, Lauren Byers⁵, Don L. Gibbons⁵, Jichao Chen⁸, Seyed Javad Moghaddam⁸, Edwin J. Ostrin⁹, Junya Fujimoto², Jerry Shay¹⁰, John V. Heymach⁵, John D. Minna⁶, Steven Dubinett¹¹, Paul A. Scheet⁴, Ignacio I. Wistuba², Edward Hill¹², Shannon Telesco¹², Christopher Stevenson¹², Avrum E. Spira^{12,13}, Linghua Wang^{1#}, Humam Kadara^{2#}

Departments of Genomic Medicine¹, Translational Molecular Pathology², Pathology³, Epidemiology⁴, Thoracic, Head and Neck Medical Oncology⁵, Cardiovascular and Thoracic Surgery⁷, Pulmonary Medicine⁸ and General Internal Medicine⁹, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hamon Center for Therapeutic Oncology Research⁶ and Department of Cell Biology¹⁰, University of Texas Southwestern, Dallas, TX, USA. Department of Medicine¹¹, The University of California Los Angeles, Los Angeles, CA, USA. Lung Cancer Initiative at Johnson and Johnson¹³, Lansdale, PA, USA. Section of Computational Biomedicine¹³, Boston University, Boston, MA, USA.

*: equally contributing co-first authors

#: equally contributing co-corresponding authors

Running title: ACE2 expression patterns in lung epithelial cells

***Correspondence to:** Linghua Wang, Ph.D., Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, email: lwang22@mdanderson.org or to Humam Kadara, Ph.D., Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, email: hkadara@mdanderson.org.

Grant support: Supported in part by research funding from Johnson and Johnson (to HK), National Cancer Institute (NCI) grants R01CA205608 (to HK), 1U2CCA233238 (to HK, SD and AES), University of Texas SPORE in Lung Cancer P50CA070907 (to JDM) and P50 core grant CA016672 (ATGC), NIH grant 1S10OD024977 and start-up research funds kindly provided to LW and HK by The University of Texas MD Anderson Cancer Center.

ABSTRACT

The novel coronavirus SARS-CoV-2 was identified as the causative agent of the ongoing pandemic COVID 19. COVID-19-associated deaths are mainly attributed to severe pneumonia and respiratory failure. Recent work demonstrated that SARS-CoV-2 binds to angiotensin converting enzyme 2 (ACE2) in the lung. To better understand *ACE2* abundance and expression patterns in the lung we interrogated our in-house single-cell RNA-sequencing dataset containing 70,085 EPCAM+ lung epithelial cells from paired normal and lung adenocarcinoma tissues. Transcriptomic analysis revealed a diverse repertoire of airway lineages that included alveolar type I and II, bronchioalveolar, club/secretory, quiescent and proliferating basal, ciliated and malignant cells as well as rare populations such as ionocytes. While the fraction of lung epithelial cells expressing *ACE2* was low (1.7% overall), alveolar type II (AT2, 2.2% *ACE2*+) cells exhibited highest levels of *ACE2* expression among all cell subsets. Further analysis of the AT2 compartment (n = 27,235 cells) revealed a number of genes co-expressed with *ACE2* that are important for lung pathobiology including those associated with chronic obstructive pulmonary disease (COPD; *HHIP*), pneumonia and infection (*FGG* and *C4BPA*) as well as malarial/bacterial (*CD36*) and viral (*DMBT1*) scavenging which, for the most part, were increased in smoker versus light or non-smoker cells. Notably, *DMBT1* was highly expressed in AT2 cells relative to other lung epithelial subsets and its expression positively correlated with *ACE2*. We describe a population of *ACE2*-positive AT2 cells that co-express pathogen (including viral) receptors (e.g. *DMBT1*) with crucial roles in host defense thus comprising plausible phenotypic targets for treatment of COVID-19.

INTRODUCTION

In late December 2019, an outbreak of lung pneumonia initially of unknown cause was reported in China ¹. This emerging disease, termed coronavirus disease 2019 (COVID-19), was soon thereafter attributed to infection with the novel zoonotically-transmitted coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ². On March 11, 2020, COVID-19 was declared a rapidly spreading global pandemic by the world health organization. As of April 12, SARS-CoV-2 has infected more than 1.8 million people worldwide resulting in over 110,000 deaths ³.

Upon SARS-CoV-2 infection, the clinical presentation of COVID-19 is diverse, ranging from asymptomatic infection and mild upper respiratory illness to pneumonia, acute respiratory distress syndrome (ARDS), respiratory failure and death ¹. Recent clinical reports have suggested that old age and comorbidities such as cardiovascular disease, chronic inflammatory lung disease and cancer are risk factors for COVID-19-associated severe pneumonia and death ¹. Recent analyses reported that COVID-19 patients who were smokers required more aggressive clinical interventions and that smoking possibly elevates the risk of COVID-19 associated pneumonia and death ^{4,5}. These findings suggest that limiting inflammatory responses by intercepting pathways involved pulmonary (and perhaps cardiac) pathobiology may represent viable strategies to improve COVID-19 patient outcomes.

Recent molecular studies have demonstrated that SARS-CoV-2 infects airway cells by binding of its spike protein to angiotensin converting enzyme 2 (ACE2), the same receptor used by SARS-CoV ^{6,7,8,9}. While SARS-CoV and SARS-CoV-2 spike proteins exhibit high degrees of homology, recent studies have demonstrated that the novel coronavirus binds ACE2 more efficiently than the original SARS-CoV virus ^{10,11,12,13}. Expression of ACE2 in the lung was suggested to implicate lung epithelial cells as routes of entry and, thus, targets for SARS-CoV-2 infection. ACE2 is a carboxypeptidase that limits activation of the renin-angiotensin system (RAS), a hormonal system that plays major roles in cardiovascular and pulmonary physiology and pathology ¹⁴. ACE2 has been shown to protect from

lung injury mediated by SARS-CoV infection which was also alleviated by targeting the RAS ¹⁵. A large body of literature suggests that the ACE2-mediated RAS axis plays important roles in lung function ¹⁴, susceptibility to the SARS virus ⁸, and inhibition of angiogenesis in lung cancer ¹⁶. However, the role of key pathways in lung pathobiology and inflammation in the pathogenesis of COVID-19, particularly in high risk individuals, remains unexplored.

Motivated by the current and unprecedented global health crisis, we leveraged our ongoing lung single-cell RNA-sequencing (scRNA-seq) efforts to interrogate the expression of the SARS-CoV-2 receptor *ACE2* in a unique cohort of 70,085 lung epithelial cells from tumor and matched uninvolved normal lung tissues from five lung adenocarcinoma (LUAD) patients. Among all lung epithelial subsets, we found that *ACE2* expression was higher in uninvolved AT2 cells and malignant epithelial cells. We interrogated single-cell gene co-expression profiles and found that *ACE2*-expressing AT2 cells concurrently expressed other genes with important yet understudied roles in lung pathobiology including fibrosis, modulation of chronic inflammation and innate host-defense mechanisms by additional viral receptors and scavengers, particularly among cells from smokers. Our single-cell analyses highlight additional possible receptors that may play a role in SARS-CoV-2 infection in the lung epithelium and, thus, are plausible targets that can be repurposed for clinical management of COVID-19.

MATERIALS AND METHODS

Derivation of single cells from lung tissues

Two to three uninvolved normal lung tissues per patient and LUADs (n = 19 samples) were collected from surgically resected specimens from five patients with early-stage disease (stages I-IIIa) (**Table 1**). All patients were evaluated at the University of Texas MD Anderson Cancer Center (MD Anderson) and had provided informed consents under approved institutional review board protocols. Fresh tissues were collected in RPMI medium supplemented with 2% fetal bovine serum (FBS) and maintained on ice for immediate processing. Tissues were placed in a cell culture dish containing Hank's balanced salt solution (HBSS) on ice and extra-pulmonary airways and connective tissue was removed with scissors. Samples were transferred to a new dish on ice and minced into tiny pieces (approximately 1mm³) followed by enzymatic digestion using a cocktail containing Collagenase A (10103578001, Sigma Aldrich), Collagenase IV (NC9836075, Thermo Fisher Scientific), DNase I, (11284932001, Sigma Aldrich), Dispase II (4942078001, Sigma Aldrich), Elastase 1 (NC9301601, Thermo Fisher Scientific) and Pronase (10165921001, Sigma Aldrich). Samples were incubated in a 37 °C oven for 10 minutes with gentle rotation and then incubated for an additional 10 minutes. Samples were then filtered through 70 µm strainers (Miltenyi biotech, 130-098-462) and washed with ice-cold HBSS. Filtrates were then centrifuged and re-suspended in ice-cold ACK lysis buffer (A1049201, Thermo Fisher Scientific) for red blood cell (RBC) lysis. Following RBC lysis, samples were centrifuged and re-suspended in ice-cold FBS, filtered (using 40 µm FlowMi tip filters; H13680-0040, Millipore). Cells were enumerated and examined for viability by Trypan blue exclusion analysis. Cells were immediately frozen in FBS containing 10% dimethyl sulfoxide and cryopreserved.

Sorting and enrichment of viable lung EPCAM+ epithelial singlets

At the time of processing, cryopreserved single cells from patient 1 were rapidly thawed, washed, and stained with SYTOX Blue viability dye (S34857, Life technologies), and processed on a FACS Aria II instrument. Cells from patients 2 through 5 were stained following washing with anti-EPCAM-PE (347198, BD Biosciences; 1:50 dilution in ice-cold phosphate-buffered saline, PBS, containing 2%

FBS) for 30 minutes. EPCAM-stained cells were then washed, filtered using 40 µm tip filters, stained with SYTOX Blue and processed on a FACS Aria II instrument. Doublets and dead cells were eliminated, and viable (SYTOX-negative) EPCAM-positive (EPCAM+, epithelial) singlets were collected in PBS containing 2% FBS. Cells were washed again to eliminate ambient RNA, and a sample was taken for counting by Trypan Blue exclusion (T8154, Sigma Aldrich) before loading on 10X Chromium microfluidic chips.

Preparation of single-cell 5' gene expression libraries

Up to 10,000 cells per sample were partitioned into nanoliter-scale Gel beads-in-emulsion (GEMs) using Chromium Next GEM Single Cell 5' Gel Bead Kit v1.1 (1000169, 10X Genomics) and by loading onto Chromium Next GEM Chips G (1000127, 10X Genomics). GEMs were then recovered to construct single-cell 5' gene expression libraries using the Chromium Next GEM Single Cell 5' Library kit (1000166, 10X Genomics) according to the manufacturer's protocol. Briefly, recovered barcoded GEMs were broken and pooled, followed by magnetic bead clean-up (Dynabeads MyOne Silane, 37002D, Thermo Fisher Scientific). 10X-barcoded full-length cDNA was then amplified via PCR and analyzed using Bioanalyzer High Sensitivity DNA kit (5067-4626, Agilent). Up to 50 ng of cDNA was carried over to construct gene expression libraries and was enzymatically fragmented and size-selected to optimize the cDNA amplicon size prior to 5' gene expression library construction. Further, samples were subject to end-repair, A-tailing, adaptor ligation, and sample index PCR using Single Index Kit T Set A (2000240, 10X Genomics) to generate Illumina-ready barcoded gene expression libraries. Library quality and yield was measured using Bioanalyzer High Sensitivity DNA kit (5067-4626, Agilent) and Qubit dsDNA High Sensitivity Assay Kit (Q32854, Thermo Fisher Scientific). Indexed libraries were normalized before pooling by adjusting for the ratio of the targeted cells per library as well as individual library concentration and pooled to a final concentration of 10 nM. Library pools were then denatured and diluted as recommended for sequencing on the Illumina NovaSeq 6000 platform.

scRNA-seq data analysis

Single-cell decoding was performed using available computational framework. Raw scRNA-seq data was pre-processed, demultiplexed, aligned to human GRCh38 reference and feature-barcodes generated using Cell Ranger (10X Genomics, version 3.0.2). Detailed quality control metrics were generated and evaluated. Genes detected in < 3 cells and cells where < 200 genes had non-zero counts were filtered out and excluded from subsequent analysis. Low quality cells where >15% of the read counts originated from the mitochondrial genome were also discarded. In addition, cells with >6,000 detected genes were discarded to remove likely doublet or multiplet captures. Possible batch effects were evaluated and corrected using Harmony ¹⁷. Raw unique molecular identifier (UMI) counts were log normalized and used for principal component analysis (PCA). We applied Seurat ¹⁸ for clustering and UMAP ¹⁹ for dimensional reduction to perform unsupervised analysis of the high-dimensional data into distinct cell clusters. EPCAM+ cells were partitioned into major airway lineage clusters, followed by subclustering within each compartment/lineage to identify subpopulations. Differentially expressed genes (DEGs) for each cell cluster were identified using the *FindAllMarkers* function in Seurat R package. The top 50 most significant DEGs were examined and an integrative approach was used to determine cell types and states.

In addition to the bioinformatics approaches described above, all other statistical analysis was performed using R v3.6.0. Analysis of differences in genes between groups (e.g., between *ACE2*-positive vs. *ACE2*-negative; smoker vs. non/light smoker) were calculated using the *FindMarkers* function in R. Pseudo-bulk gene expression values for defined cell clusters were calculated by taking mean expression of each gene across all cells in a specific cluster. Deconvolution of AT2 cell abundance was performed on the TCGA lung adenocarcinoma cohort by incorporating AT2 signature genes defined by our study into MCP-counter, an R package that permits the quantification of the absolute abundance of immune and stromal cell populations in heterogeneous tissues from transcriptome data ²⁰. All statistical significance testing was two-sided, and results were considered statistically significant at p-value < 0.05. The Benjamini-Hochberg method was applied to control the

false discovery rate (FDR) in multiple comparisons (e.g. DEG analysis), and calculate adjusted p-values (q-values).

RESULTS

Single-cell decoding of normal and malignant lung epithelial cells

We performed single-cell analysis of normal lung tissues and matched treatment-naïve early-stage lung adenocarcinomas (LUADs) from five patients using droplet based scRNA-seq. We first processed two normal lung tissues and a LUAD from patient 1 which resulted in 15,370 cells that were retained for analysis. In line with studies of other organs²¹, we noted that the fraction of epithelial (*EPCAM*+) cells attained by unbiased analysis of lung tissues was limited (~4%, n = 624 cells) (**Table 2**). To better capture lung epithelial cells, including their heterogeneity, we performed single-cell analysis of fluorescent-activated cell sorting (FACS) enriched *EPCAM*+ cells from three normal lung tissues (per patient) and LUADs from four additional patients. Using this strategy, we were able to capture on average 20-fold more lung epithelial cells (**Table 2**). Following quality control and filtering, we retained 70,085 lung epithelial cells from the 19 samples (5 tumor samples, n = 13,134 cells; 14 normal lung tissues, n = 56,951 cells) (**Fig. 1a**). We achieved on average 146,574 reads, 9,202 unique molecular identifiers and 2,407 genes per cell (**Table 2**). Unsupervised clustering analysis identified a diverse repertoire of airway lineages which were divided into 10 cell clusters with distinct transcriptomic features (e.g., expression of lineage-specific markers) (**Fig. 1a**). These cell clusters covered major lineages of lung epithelium such as alveolar type I (AT1; n = 10,775; *AGER*, *EMP2*, *CAV1*), AT2 (n = 27,235; *SFTPC*, *SFTPB*, *PGC*), club and secretory (n = 4,625; *SCGB1A1*, *SCGB3A1*, *SCGB3A2*), ciliated (n = 3,247; *FOXJ1*, *CAPS*, *PIFO*) and basal cells (n = 5,119; *KRT17*, *KRT15*, *TP63*) including those with proliferative properties (n = 449; *MKI67*, *TOP2A*) (**Fig. 1c** and **Fig. S1**). One cluster included bronchioalveolar cells that were enriched for markers of both AT2 and club lineages (**Fig. 1b**). We also identified alveolar transitory or progenitor cells which expressed both AT2 and AT1 markers including *HOPX* as well as *KRT7* (**Fig. 1c**) in line with previous reports^{22, 23}. Clustering analysis also revealed a rare cell population that exclusively expressed *ASCL3* and *FOXI*

(**Fig. 1c** and **Fig. S1**) characteristic of pulmonary ionocytes which were recently described by single-cell analysis^{24, 25}. Of note, most cells from the LUAD specimens clustered distinctly from cells of uninvolved lung tissues and exhibited the highest expression of the tumor marker *CEACAM5* and mixed lineage genes (**Fig. 1b-c**) thus representing diverse lung malignant cells in line with recent studies²⁶.

Abundance and expression patterns of the SARS-CoV-2 receptor *ACE2* in lung epithelium

The ongoing COVID-19 pandemic caused by infection with the novel coronavirus SARS-CoV-2 prompted us to leverage our lung scRNA-seq dataset and interrogate expression patterns of the SARS-Cov-2 receptor *ACE2* in lung epithelial cells. We found that the fraction of *ACE2*-expressing cells among all lung epithelial cells was low (n= 1,208, 1.7%) (**Fig. 2a**). The highest fractions of *ACE2*-expressing cells were found in the malignant (3.5%), AT2 (2.2%) and club/secretory (2.4%) cell clusters (**Fig. 2a**). Among those clusters with > 1% *ACE2*-positive cells, AT2 cells expressed the highest expression of *ACE2* (**Fig. 2b**). We then explored expression patterns of other members of the RAS²⁷ (**Fig. 2c**). Of note, RAS genes were expressed at low levels in AT2 cells compared to other epithelial cell subsets and AT1 cells exhibited relatively higher expression of various RAS members such as adrenergic 2 beta receptor (*ADRB2*) (**Fig. 2c**). We then examined *ACE2* expression in subclusters of AT2 and malignant cells, the two populations with relatively highest fraction of cells positive for the SARS-CoV-2 receptor (**Fig. S2**). The AT2 subcluster (AT2_c2) with relatively highest expression of *ACE2* (**Fig. S2a** and **Fig. S2b**) exhibited similar levels of RAS genes compared to other AT2 subclusters except for elevated expression of amyloid precursor protein (*APP*) and the carboxypeptidase *CPM* (**Fig. S2c**). Similarly, we did not find similar patterns of expression between *ACE2* and other members of the RAS among the malignant cell subclusters (**Figs. S2c-e**). Earlier studies have shown that antihypertensive drugs such as losartan may impact expression levels of *ACE2*^{28, 29}. We thus analyzed *ACE2* expression in AT2 and lung malignant cells based on whether patients were on antihypertensive drugs. Interestingly, while the fractions of *ACE2*-positive AT2 and malignant cells were lower in losartan-treated patients, levels of *ACE2* expression in those cells were

significantly higher in losartan treated patients ($P < 10^{-16}$; **Fig. S3**). We also examined the expression and abundance patterns of *TMPRSS2*, a serine protease recently shown to be crucial for SARS-CoV-2 spike protein priming upon host cell entry ⁶, as well as *ADAM17*, a sheddase that was shown to cleave (shed) *ACE2* ³⁰. *TMPRSS2* expression level and frequency were highest in AT2 cells among all lung subsets, whereas *ADAM17* expression levels were highest in malignant cells (**Fig. S4**). Also, among AT2 cells, expression levels of *TMPRSS2* and *ADAM17* were highest in the same AT2 subcluster as *ACE2* (**Figs. S2b and S4b**).

We next sought to identify differentially expressed genes (DEGs) in AT2 cells based on *ACE2* expression. A cutoff of absolute gene expression fold-change >1.2 and an FDR q-value < 0.05 were applied to select DEGs between *ACE2*-expressing and *ACE2*-absent AT2 cells. We found genes up-regulated in *ACE2*-expressing AT2 cells that are highly pertinent to lung epithelial biology and disease such as *HHIP* (lung branching and chronic obstructive pulmonary disease/COPD, ^{31, 32}), *FGG* (fibrosis, pneumonia and inflammation, ^{33, 34}) and *C4BPA* (complement system, pneumonia and infection, ^{35, 36}) (**Fig. 3**). In addition, we found that *ACE2*-expressing AT2 cells exhibited significantly higher expression of scavengers such as *CD36* ³⁷ and *DMBT1*, a pattern recognition receptor that plays crucial host defense roles against bacterial and viral pathogens including influenza A and human immune deficiency virus I (HIV-I) ³⁸. Interestingly, *DMBT1* expression was markedly and distinctly highest in AT2 cells relative to other lung cell subsets (**Fig. S5a**). Also, *DMBT1* expression in AT2 cells was higher compared to other coronavirus receptors such as the MERS-CoV receptor *DPP4* ^{39, 40} and *BSG* (also known as CD147) which was recently suggested to represent a potential alternate route of entry for SARS-CoV-2 ⁴¹ (**Fig. S5a**). Also, *DMBT1* displayed similar patterns of expression with *ACE2* among AT2 (**Fig. S5b**) and lung malignant cell (**Fig. S5c**) subclusters.

Recently, expansion of *ACE2*-expressing lung epithelia in response to cigarette smoke has also been proposed ⁴² and smoking was shown to activate the RAS ⁴³. We were thus enticed to compare the identified *ACE2*-co-expressed genes, along with members of the RAS, in lung epithelial cells based

on patient smoking status. We identified genes differentially expressed between AT2 cells derived from smokers (at least 20 pack year smoking history, $n = 10,901$ cells) and those from non- or light-smokers (less than five pack years, $n = 16,334$ cells) based on a q-value threshold of 0.05 and a fold-change cut-off of 1.5 (**Fig. 4a**). While *ACE2* itself was not modulated by smoking status, we found that the virus receptor and scavenger *DMBT1*, as well as *FGG* and *C4BPA*, were significantly increased in smoker compared to non/light smoker AT2 cells (**Fig. 4a-b**). *DMBT1* was not significantly differentially modulated among malignant cells based on smoking status (**Fig. 4c**), though we found increased expression of *BSG* and members of the RAS (mostly kallikreins) in smoker ($n = 9,047$) compared to non/light smoker ($n = 1,657$) malignant cells (**Fig. 4c-d**).

Our findings on the significant associations between *ACE2* and *DMBT1* prompted us to probe the correlation of both genes in the AT2 compartment. We performed pseudo-bulk analysis of the AT2 cluster (by sample) in our cohort and found that *DMBT1* and *ACE2* exhibited positive correlation ($R = 0.3$) albeit not reaching statistical significance (**Fig. 5a**). To validate this finding in larger cohorts, we performed deconvolution analysis of bulk RNA-seq data of the cancer genome atlas (TCGA) LUAD cohort to estimate the abundance of AT2 cells in normal lung tissues ($n = 110$). Both *DMBT1* and *ACE2* expression levels significantly and positively correlated with AT2 fractions (indicated by the AT2 meta-score, $P < 0.05$) (**Fig. 5b**). Interestingly, *BSG*, the other recently proposed entry point for SARS-CoV-2, also significantly and positively correlated with the AT2 meta-score in the normal lung tissues ($P < 0.05$) (**Fig. 5b**). Similar results were obtained with *TMPRSS2* ($P < 0.05$) but not *ADAM17* (**Fig. S6a**). Further, among TCGA normal lung tissues with high AT2 fractions (meta-score > 15.47), *DMBT1* expression significantly and positively correlated with *ACE2* ($R = 0.41$, $P < 0.05$) (**Fig. 5c**). We did not find significant correlation between *ACE2* and *TMPRSS2* nor with *ADAM17* in the TCGA lung tissues by deconvolution analysis (**Fig. S6b**). Our findings point to specific *ACE2*-expressing AT2 cells that also co-express other pathogen receptors and scavengers (e.g. *DMBT1*) thus possibly representing a minute subpopulation in the lung with unique host defense properties and functions.

DISCUSSION

We interrogated our relatively large in-house single-cell RNA-sequencing dataset of 70,085 lung epithelial cells to examine abundance and expression patterns of the SARS-CoV-2 receptor *ACE2*. While *ACE2* was expressed in a low fraction of lung epithelial cells (roughly 1.7%), its levels among all lung cell subsets were highest in AT2 cells. *ACE2*-expressing AT2 cells co-expressed genes with crucial roles in lung pathological conditions such as COPD, pneumonia and pathogen infection including the viral binding scavenger *DMBT1* and which overall were higher in cells derived from smokers relative to non/light smokers. We also found that *DMBT1* positively correlated with AT2 cell fractions and with *ACE2* itself within the AT2 compartment. Our findings suggest that *ACE2*-expressing cells in the lung are relatively scarce, they exhibit unique molecular and biological features that are pertinent to antiviral and host defense functions by the lung epithelium.

Our findings on expression of *ACE2* in AT2 cells are in line with previous studies ^{44, 45}. Hamming et al showed abundant immunohistochemical expression of ACE2 protein in AT2 cells in the lung ⁴⁵. *Ace2* was shown to not only to be expressed in AT2 cells in the mouse lung but also to regulate alveolar epithelial cell survival ⁴⁶. Of note, Mossel and colleagues demonstrated that SARS-CoV, by binding to ACE2, replicates primarily in AT2 and not AT1 cells ⁴⁴. Also, AT2 cells were shown to be primarily responsible in the lung for an innate immune response against infection with SARS-CoV ⁴⁷.

Interestingly, a very recent preprint by Zhao and colleagues revealed that *ACE2* expression was concentrated in a small population (~1.4%) of AT2 cells ⁴⁸. Our findings are in very close agreement with the preprint by Zhao et al in which we find that the SARS-CoV-2 receptor *ACE2* is expressed in a minute fraction of AT2 cells (~2.2%). Here, we further interrogated a relatively larger and more diverse repertoire of airway lineages, from both normal and lung tumor (LUAD) tissues, and found that *ACE2* expression was not only highest in AT2 cells but also that malignant cells exhibited the highest *ACE2*-positive fraction. It is worthwhile to mention that patients with cancer, including lung malignancy, may represent a population that is extremely vulnerable to COVID-19 ⁴⁹. Our finding on expression of *ACE2* in lung malignant (adenocarcinoma) cells may have implications for the management of

COVID-19 in lung cancer and clinical studies are warranted to explore this conjecture. Our analysis also revealed significantly elevated *ACE2* levels, among *ACE2*-positive AT2 and malignant cells, in patients who were on hypertension treatment with losartan compared to those without antihypertensive therapy. While our finding is in line with previous reports suggesting that antihypertensive agents may augment *ACE2* expression^{28, 29, 50}, it needs to be interpreted with caution. Our patient cohort is very limited in size and our study was designed with a focus on single-cell analysis of lung epithelial cells. We thus cannot construe the implications of this finding on COVID-19 management^{50, 51} and further studies are warranted to better (e.g., larger cohort) explore the association between treatment with antihypertensive drugs and *ACE2* expression in human cells.

We found that *ACE2*-positive compared to *ACE2*-negative AT2 cells exhibited increased levels of genes with crucial roles and expression features in lung pathological diseases. The hedgehog interacting protein *HHIP* was not only shown to play important roles in airway branching during lung development³², but also single nucleotide polymorphisms of this gene are associated with increased risk for COPD³¹, a pulmonary ailment characterized by chronic inflammation⁵². *FGG* coding for fibrinogen-gamma was shown to be induced by pro-inflammatory cytokines³⁴ and to be elevated in lung pneumonia and infection³³. *C4BPA*, coding for C4BP and part of the complement system, was found to recognize and bind pneumonia-causing streptococci in the lung epithelium^{35, 36}. It is noteworthy that many patients with COVID-19 (e.g. those with severe disease) commonly display the same pathological phenotypes, namely lung inflammation, fibrosis, and pneumonia, linked to those *ACE2*-co-expressed genes. It is intriguing to suggest that perhaps this small population of *ACE2*-expressing cells may underlie the pathogenesis of severe acute respiratory distress syndrome, pneumonia and respiratory failure in COVID-19 patients. It is important to note that emerging studies are showing that males are disproportionately affected by COVID-19, possibly due to sex-based immunological bias or differences in smoking patterns and prevalence⁵³. Also, a recent preprint suggested that smoking causes expansion of *ACE2*-expressing lung epithelia⁴². Interestingly, several of the *ACE2*-co-expressed genes we identified (*FGG*, *DMBT1*, *C4BPA*) were elevated in smoker AT2

cells. Of note, smoking increases lung inflammation and the risk for various lung diseases including interstitial lung fibrosis, pneumonia and COPD ⁵⁴. It is plausible that smoking may augment SARS-CoV-2 entry in the lung and COVID-19 pathogenesis, a supposition that warrants future studies.

A notable finding in our study was the co-expression of pathogen including viral scavengers and receptors such as *CD36* and *DMBT1* in *ACE2*-positive AT2 cells. We also found that among all lung subsets, AT2 cells distinctly and markedly displayed the highest expression of *DMBT1*. Further, *DMBT1* correlated with AT2 fractions in independent cohorts of bulk-sequenced lung tissues and positive correlated with *ACE2* in the AT2 compartment. *DMBT1*, also known as gp340, was shown to inhibit influenza A by binding to hemagglutinin (HA) on the virus ⁵⁵. *DMBT1* was also shown to interact with surfactant protein D (SFTPD) in alveolar cells to agglutinate and inhibit influenza A virus ³⁸. It has been suggested that the antiviral drug oseltamivir cooperates with innate immune proteins such as *DMBT1* in inhibition of lung epithelial cell infection by influenza A virus ⁵⁵. Interestingly soluble *DMBT1* in saliva was shown to exert host defense roles (neutralization or inhibition of oral transmission) against influenza A virus ⁵⁵ as well as HIV-1 ⁵⁶. *DMBT1* was shown to specifically inhibit HIV-1 infectivity by binding to the virus envelope protein gp120, the same protein that binds to the CD4 receptor on T cells in the host ⁵⁷. Intriguingly, very much like emerging reports on *ACE2* acting as an entry route in the lung that facilitates SARS-CoV-2 infection ⁶, *DMBT1* was shown to aid in HIV-1 transcytosis across genital tract tissue ⁵⁸. Also, the study by Stoddard and colleagues demonstrated that transport of HIV-1 can be inhibited by antibodies or peptides that block the interaction of *DMBT1* with the HIV-1 envelope protein gp120 ⁵⁸. Given our findings on *DMBT1* expression in lung AT2 cells and its co-expression with *ACE2*, as well as its reported binding with multiple viruses, we suggest that targeting *DMBT1*, whether by adding soluble *DMBT1*-derive peptides ⁵⁹ or by antibody-based neutralization, may represent a viable strategy to counteract SARS-CoV-2 infection and ameliorate COVID-19.

In conclusion, single-cell transcriptomic analysis of our lung epithelial cell cohort demonstrated that among all lung cell subsets AT2 cells displayed highest relative expression of the SARS-CoV-2 receptor *ACE2*, albeit at a low cell fraction (~2.2% of all AT2 cells). We found that the viral scavenger *DMBT1* is highly expressed in AT2 cells and correlates with *ACE2* in this compartment. Our study points to a scarce *ACE2*-expressing AT2 population that also expresses genes involved in inflammatory lung pathological conditions (e.g., pneumonia) and in host defense and, thus, could be exploited (or repurposed) as phenotypic targets for treatment of SARS-CoV-2 infection and COVID-19 disease.

Table 1. Clinicopathological variables of the LUAD patients analyzed by scRNA-seq

Patient	Stage	Age	Smoking status	Sex	Ethnicity
P1	IIIA	70	Non-smoker	Female	White or Caucasian
P2	IB	73	Former	Female	White or Caucasian
P3	IIIA	58	Light former*	Female	White or Caucasian
P4	IIB	64	Former	Female	White or Caucasian
P5	IB	71	Non-smoker	Male	White or Caucasian

*light smoker (less than five pack-years of smoking)

Table 2. Number of EPCAM+ cells analyzed in normal lung and LUAD tissues

Sample	Mean reads/cell	Median genes/cell	Median UMI counts/cell	EPCAM+ cells
P1-Normal 1	52,655	1,522	4,477	209
P1-Normal 2	74,717	1,564	4,473	231
P1-LUAD	63,323	1,558	5,043	184
P2-Normal 1	78,527	2,356	6,697	5,308
P2-Normal 2	71,131	2,335	6,772	6,093
P2-Normal 3	91,714	2,464	7,849	4,284
P2-LUAD	124,227	2,455	8,100	3,080
P3-Normal 1	65,482	861	1,790	5,118
P3-Normal 2	167,751	2,803	10,432	2,760
P3-Normal 3	364,619	2,785	10,262	1,171
P3-LUAD	131,897	3,823	20,358	2,784
P4-Normal 1	136,196	1,956	5,355	3,909
P4-Normal 2	148,772	2,677	8,221	4,527
P4-Normal 3	125,188	2,390	7,585	5,853
P4-LUAD	601,893	2,659	8,403	715
P5-Normal 1	67,854	1,880	5,070	1,610
P5-Normal 2	39,243	1,296	3,307	7,999
P5-Normal 3	49,886	1,303	3,504	7,879
P5-LUAD	80,800	1,839	4,536	6,371

LUAD, lung adenocarcinoma

REFERENCES

1. WorldHealthOrganization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 14-20 February 2020. (2020).
2. Zhu N, *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* **382**, 727-733 (2020).
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*, (2020).
4. Guan WJ, *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, (2020).
5. Qi D, *et al.* Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. *medRxiv*, 2020.2003.2001.20029397 (2020).
6. Hoffmann M, *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, (2020).
7. Zhou P, *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273 (2020).

8. Kuba K, *et al.* A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* **11**, 875-879 (2005).

9. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, (2020).

10. Haga S, *et al.* Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. *Proc Natl Acad Sci U S A* **105**, 7809-7814 (2008).

11. Yang Y, *et al.* Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. *Proc Natl Acad Sci U S A* **111**, 12516-12521 (2014).

12. Yang Y, *et al.* Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. *J Virol* **89**, 9119-9123 (2015).

13. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol* **94**, (2020).

14. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. *Curr Cancer Drug Targets* **11**, 394-404 (2011).

15. Imai Y, *et al.* Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* **436**, 112-116 (2005).
16. Feng Y, *et al.* The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. *Oncol Rep* **23**, 941-948 (2010).
17. Korsunsky I, *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods* **16**, 1289-1296 (2019).
18. Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol* **33**, 495-502 (2015).
19. Becht E, *et al.* Dimensionality reduction for visualizing single-cell data using UMAP. *Nat Biotechnol*, (2018).
20. Becht E, *et al.* Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol* **17**, 218 (2016).
21. Aizarani N, *et al.* A human liver cell atlas reveals heterogeneity and epithelial progenitors. *Nature* **572**, 199-204 (2019).
22. Ota C, *et al.* Dynamic expression of HOPX in alveolar epithelial cells reflects injury and repair during the progression of pulmonary fibrosis. *Sci Rep* **8**, 12983 (2018).

23. Jain R, *et al.* Plasticity of Hopx(+) type I alveolar cells to regenerate type II cells in the lung. *Nat Commun* **6**, 6727 (2015).

24. Plasschaert LW, *et al.* A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. *Nature* **560**, 377-381 (2018).

25. Montoro DT, *et al.* A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. *Nature* **560**, 319-324 (2018).

26. Laughney AM, *et al.* Regenerative lineages and immune-mediated pruning in lung cancer metastasis. *Nat Med* **26**, 259-269 (2020).

27. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. *Nat Rev Cancer* **10**, 745-759 (2010).

28. Klimas J, *et al.* Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. *J Cell Mol Med* **19**, 1965-1974 (2015).

29. Ferrario CM, *et al.* Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* **111**, 2605-2610 (2005).

30. Xu J, *et al.* Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. *Circ Res* **121**, 43-55 (2017).

31. Zhou X, *et al.* Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. *Hum Mol Genet* **21**, 1325-1335 (2012).

32. Chuang PT, McMahon AP. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. *Nature* **397**, 617-621 (1999).

33. Simpson-Haidaris PJ, Courtney MA, Wright TW, Goss R, Harmsen A, Gigliotti F. Induction of fibrinogen expression in the lung epithelium during *Pneumocystis carinii* pneumonia. *Infect Immun* **66**, 4431-4439 (1998).

34. Duan HO, Simpson-Haidaris PJ. Cell type-specific differential induction of the human gamma-fibrinogen promoter by interleukin-6. *J Biol Chem* **281**, 12451-12457 (2006).

35. Haleem KS, *et al.* The Pneumococcal Surface Proteins PspA and PspC Sequester Host C4-Binding Protein To Inactivate Complement C4b on the Bacterial Surface. *Infect Immun* **87**, (2019).

36. Buffalo CZ, *et al.* Conserved patterns hidden within group A *Streptococcus* M protein hypervariability recognize human C4b-binding protein. *Nat Microbiol* **1**, 16155 (2016).

37. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. *Sci Signal* **2**, re3 (2009).

38. Madsen J, Mollenhauer J, Holmskov U. Review: Gp-340/DMBT1 in mucosal innate immunity. *Innate Immun* **16**, 160-167 (2010).
39. Reinhold D, Brocke S. DPP4-directed therapeutic strategies for MERS-CoV. *Lancet Infect Dis* **14**, 100-101 (2014).
40. Raj VS, *et al.* Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* **495**, 251-254 (2013).
41. Wang K, *et al.* SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. *bioRxiv*, 2020.2003.2014.988345 (2020).
42. Smith JC, Sheltzer JM. Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2. *bioRxiv*, 2020.2003.2028.013672 (2020).
43. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. *Am J Physiol Regul Integr Comp Physiol* **315**, R895-r906 (2018).
44. Mossel EC, *et al.* SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. *Virology* **372**, 127-135 (2008).

45. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* **203**, 631-637 (2004).
46. Uhal BD, Li X, Xue A, Gao X, Abdul-Hafez A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. *Am J Physiol Lung Cell Mol Physiol* **301**, L269-274 (2011).
47. Qian Z, *et al.* Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. *Am J Respir Cell Mol Biol* **48**, 742-748 (2013).
48. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. *bioRxiv*, 2020.2001.2026.919985 (2020).
49. Liang W, *et al.* Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* **21**, 335-337 (2020).
50. Kreutz R, *et al.* Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. *Cardiovasc Res*, (2020).
51. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*, (2020).
52. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* **138**, 16-27 (2016).

53. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. *Lancet* **395**, 846-848 (2020).
54. National Center for Chronic Disease P, Health Promotion Office on S, Health. Reports of the Surgeon General. In: *The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General*). Centers for Disease Control and Prevention (US) (2014).
55. White MR, *et al.* Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor. *Am J Physiol Lung Cell Mol Physiol* **288**, L831-840 (2005).
56. Wu Z, *et al.* Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. *AIDS Res Hum Retroviruses* **19**, 201-209 (2003).
57. Yoon V, Fridkis-Hareli M, Munisamy S, Lee J, Anastasiades D, Stevceva L. The GP120 molecule of HIV-1 and its interaction with T cells. *Curr Med Chem* **17**, 741-749 (2010).
58. Stoddard E, *et al.* gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. *J Virol* **83**, 8596-8603 (2009).
59. Tuttolomondo M, *et al.* Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery. *Mol Ther Nucleic Acids* **8**, 264-276 (2017).

FIGURE LEGENDS

Figure 1: Overview of 70,085 EPCAM+ lung epithelial cells analyzed by scRNA-seq. UMAP plots with cells labeled by lineage (a) and sample type (b). AT1: alveolar type I cells; AT2: alveolar type II cells; LUAD: lung adenocarcinoma. c) Bubble plots showing cell fractions with scaled expression of airway lineage markers for the identified lung epithelial cell clusters.

Figure 2: Single-cell expression analysis of *ACE2* and genes of the RAS in lung epithelium. a) Fraction of cells expressing the SARS-CoV-2 receptor *ACE2* in major airway lineage clusters. b) *ACE2* expression level (in *ACE2*-positive cells) among three airway lineage clusters with highest fractions of *ACE2*-expressing cells. c) Bubble plots showing cell fractions with scaled expression of genes of the RAS across the identified lung epithelial cell clusters.

Figure 3: Differentially expressed genes between *ACE2*-expressing and -absent AT2 cells. a) Volcano plot showing significantly DEGs between *ACE2*-expressing (n = 607) an-absent (n = 26,628) AT2 cells. A cutoff of absolute gene expression fold-change >1.2 and an FDR q-value < 0.05 were applied to identify the DEGs. b) Violin plots showing significant up-regulation of *C4BPA*, *DMBT1* and *FGG* genes in *ACE2*-expressing compared with -absent AT2 cells, FC: Fold change.

Figure 4: Differentially expressed genes between AT2 and lung malignant cells from smoker and non/light smoker patients. a) Volcano plot showing significantly DEGs between AT2 cells from smoker (n = 10,901 cells) and non/light smoker (n = 16,334 cells) patients. b) Violin plot showing significant upregulation of *FGG*, *C4BPA* and *DMBT1* in smoker AT2 cells. c) Volcano plot showing significantly DEGs between malignant cells from smoker (n = 9,047 cells) and non/light smoker (n = 1,657) patients. d) Violin plots of select significantly up-regulated genes in smoker malignant cells. A cutoff of absolute gene expression fold-change >1.2 and an FDR q-value < 0.05 were applied to identify the DEGs. FDR q-values < 1×10^{-300} were trimmed to 1×10^{-300} for graphical purposes.

Figure 5: Expression of the viral scavenger *DMBT1* correlates with that of *ACE2* in lung AT2

cells. a) Correlation between *ACE2* and *DMBT1* expression in pseudo-bulk data from this study. **b)**

Scatter plots showing correlations between estimated AT2 cell fractions and *ACE2*, *DMBT1* and *BSG*

in TCGA normal lung samples. **c)** Significant correlation between *ACE2* and *DMBT1* in TCGA normal

lung samples with high AT2 cell fractions (meta-score > 15.47). Correlations were statistically

analyzed using Pearson's correlation coefficient.

Figure 1

Figure 2

Figure 3

a

b

Figure 4

Figure 5

a

b

Deconvolution of AT2 fractions in normal lung tissues from TCGA

c

AT2-high normal lung samples (n = 27)

Figure S1

a

Figure S2

Figure S3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.045617>; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure S4

a

b

c

Figure S5

a

b

c

Figure S6

a

Deconvolution of AT2 fractions in normal lung tissues from TCGA (n = 110)

b

AT2-high normal lung samples (n = 27)